Please try another search
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Name | Age | Since | Title |
---|---|---|---|
Bronson Crouch | 48 | 2018 | Chairman & CEO |
George Matcham | 68 | 2018 | Independent Non-Employee Director |
Neil W. Gibson | 66 | 2020 | Lead Independent Non-Employee Director |
Richard Kent McGaughy | 50 | 2020 | Independent Non-Employee Director |
Gwendolyn K. Binder | 48 | 2020 | Independent Non-Employee Director |
Jack Beck Nielsen | 59 | 2020 | Independent Non-Employee Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review